Can We Slow Aging? Rapamycin with Dr. Matt Kaeberlein

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Can We Slow Aging? Rapamycin with Dr. Matt Kaeberlein

Ascolta gratuitamente

Vedi i dettagli del titolo

A proposito di questo titolo

In this episode, Elizabeth Tringali sits down with Dr. Matt Kaeberlein, a leading aging researcher focused on the mechanisms that drive aging, including mTOR signaling and the drug rapamycin.

Matt breaks down what mTOR actually is (and why it matters), why longevity medicine requires evidence and comfort with uncertainty, and what we can realistically conclude from animal data vs. human data. You’ll hear a clear, science-first conversation on rapamycin: immune modulation vs. “immune suppression,” common side effects, why weekly dosing is different than transplant dosing, and what early findings suggest for APOE4 carriers, post-viral syndromes like long COVID, and chronic inflammation.

They also zoom out to the foundations Matt believes move the needle most: the four pillars he uses at OptiSpan (eat, move, sleep, connect), plus practical guidance on protein, fiber, CGMs, and why fear-based wellness marketing is a problem. Finally, Matt shares an update on the Dog Aging Project’s randomized rapamycin trial—one of the most fascinating real-world studies in the field—and what he expects the next 20 years of longevity medicine to look like.